SWOG clinical trial number
SWOG-9032

A Controlled Trial of Cyclosporine As A Chemotherapy-Resistance Modifier in Blast Phase-Chronic Myelogenous Leukemia

Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Controlled Trial of Cyclosporine As A Chemotherapy-Resistance Modifier in Blast Phase-Chronic Myelogenous Leukemia
Activated
06/01/1992
Closed
03/01/1998

Research committees

Leukemia

Publication Information Expand/Collapse

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2006

Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia

T Pabst;E Stillner;D Neuberg;S Nimer;CL Willman;AF List;JV Melo;DG Tenen;BU Mueller British Journal of Haematology 133:400-402

2002

Cyclosporine inhibitionof P-glycoprotein in chronic myeloid leukemia blast phase

AF List;KJ Kopecky;CL Willman;DR Head;ML Slovak;D Douer;SR Dakhil;FR Appelbaum Blood 100(5):1910-1912

1999

A randomized phase III study of cyclosporine (CsA) modulation of anthracycline resistance in CML-blast phase: Southwest Oncology Group (SWOG) study 9032

AF List;KJ Kopecky;ML Slovak;CL Willman;DR Head;FR Appelbaum Blood 94(10)Suppl.1:276b(#4445)part_2_of_2

Other Clinical Trials

SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase